微信公众号
证券之星APP
| 报告期 | 销售毛利率 | 同比 | 环比 | 行业排名 | 行业均值 | 行业龙头股 | 龙头股该指标值 | 查看 |
|---|---|---|---|---|---|---|---|---|
| 2025-09-30 | 61.91% | 1.28% | 1.34% | 46/159 | -1.59% | 海创药业 | 99.57% | 行业排名> |
| 2025-06-30 | 61.09% | -0.23% | -6.92% | 49/159 | 15.28% | 海创药业 | 99.52% | 行业排名> |
| 2025-03-31 | 65.63% | 10.01% | 5.7% | 35/159 | 32.3% | 艾力斯 | 96.74% | 行业排名> |
| 2024-12-31 | 62.09% | 8.16% | 1.58% | 47/159 | 51.78% | 首药控股 | 98.96% | 行业排名> |
| 2024-09-30 | 61.12% | 4.57% | -0.17% | 49/159 | 22.81% | 迪哲医药 | 97.73% | 行业排名> |
| 2024-06-30 | 61.23% | 5.87% | 2.63% | 49/159 | 33.25% | 百利天恒 | 97.99% | 行业排名> |
| 2024-03-31 | 59.66% | 3.11% | 3.92% | 52/159 | 51.56% | 百利天恒 | 98.92% | 行业排名> |
| 2023-12-31 | 57.41% | -2.44% | -1.78% | 63/159 | 51.39% | 迈威生物 | 98.93% | 行业排名> |
| 2023-09-30 | 58.45% | 0.71% | 1.06% | 61/159 | 32.56% | 迈威生物 | 99.59% | 行业排名> |
| 2023-06-30 | 57.83% | -0.77% | -0.05% | 60/159 | 38.45% | 迈威生物 | 99.8% | 行业排名> |
| 2023-03-31 | 57.86% | 1.36% | -1.67% | 59/159 | 52.78% | 迈威生物 | 99.46% | 行业排名> |
| 2022-12-31 | 58.84% | -6.08% | 1.39% | 59/159 | 53.66% | 迈威生物 | 99.75% | 行业排名> |
| 2022-09-30 | 58.04% | -6.68% | -0.42% | 62/159 | 6.2% | 迈威生物 | 99.67% | 行业排名> |
| 2022-06-30 | 58.28% | -8.16% | 2.1% | 63/159 | 21.37% | 迈威生物 | 99.44% | 行业排名> |
| 2022-03-31 | 57.08% | -12.18% | -8.89% | 65/159 | 54.28% | 迈威生物 | 98.57% | 行业排名> |
| 2021-12-31 | 62.65% | -5.31% | 0.75% | 60/159 | 55.1% | 首药控股 | 99.93% | 行业排名> |
| 2021-09-30 | 62.19% | -5.26% | -2% | 50/159 | 46.78% | 艾力斯 | 99.41% | 行业排名> |
| 2021-06-30 | 63.46% | -0.94% | -2.37% | 52/159 | 47.23% | 艾力斯 | 98.7% | 行业排名> |
| 2021-03-31 | 65% | 0.48% | -1.76% | 39/159 | 53.99% | 艾力斯 | 99.4% | 行业排名> |
| 2020-12-31 | 66.17% | -14.61% | 0.8% | 46/159 | -145.9% | 首药控股 | 99.94% | 行业排名> |
| 2020-09-30 | 65.64% | -16.46% | 2.46% | 40/159 | 56.36% | 泽璟制药 | 99.96% | 行业排名> |
| 2020-06-30 | 64.06% | -19.1% | -0.96% | 44/159 | 54.11% | 微芯生物 | 95.14% | 行业排名> |
| 2020-03-31 | 64.69% | -18.81% | -16.52% | 38/159 | 55.23% | 多瑞医药 | 95.59% | 行业排名> |
| 2019-12-31 | 77.49% | -7.32% | -1.38% | 24/159 | -1222.98% | 微芯生物 | 95.81% | 行业排名> |
| 2019-09-30 | 78.57% | -6.57% | -0.78% | 15/159 | 55.21% | 微芯生物 | 96.09% | 行业排名> |
| 2019-06-30 | 79.19% | -8.37% | -0.62% | 18/159 | 55.21% | 微芯生物 | 96.11% | 行业排名> |
| 2019-03-31 | 79.68% | -6.81% | -4.7% | 13/159 | 51.05% | 微芯生物 | 95.5% | 行业排名> |
| 2018-12-31 | 83.61% | -3.87% | -0.58% | 18/159 | -208.09% | 微芯生物 | 96.27% | 行业排名> |
| 2018-09-30 | 84.09% | -3.24% | -2.69% | 11/159 | 53.97% | 贝达药业 | 95.47% | 行业排名> |
| 2018-06-30 | 86.42% | -2.41% | 1.08% | 8/159 | 53.39% | 贝达药业 | 95.51% | 行业排名> |
| 2018-03-31 | 85.5% | -3.87% | -1.7% | 7/159 | 53.9% | 贝达药业 | 95.54% | 行业排名> |
| 2017-12-31 | 86.97% | 0.02% | 0.07% | 8/159 | 52.32% | 贝达药业 | 95.74% | 行业排名> |
| 2017-09-30 | 86.91% | -0.3% | -1.85% | 4/159 | 49% | 退市金泰 | 96.19% | 行业排名> |
| 2017-06-30 | 88.55% | 0.92% | -0.43% | 3/159 | 47.74% | 贝达药业 | 95.81% | 行业排名> |
| 2017-03-31 | 88.94% | 1.92% | 2.28% | 3/159 | 46.55% | 退市金泰 | 95.93% | 行业排名> |
| 2016-12-31 | 86.95% | -0.98% | -0.25% | 6/159 | 48.19% | 贝达药业 | 95.58% | 行业排名> |
| 2016-09-30 | 87.17% | -1.08% | -0.65% | 3/159 | 45.76% | 贝达药业 | 95.89% | 行业排名> |
| 2016-06-30 | 87.74% | -0.29% | 0.55% | 3/159 | 45.89% | 微芯生物 | 97.46% | 行业排名> |
| 2016-03-31 | 87.26% | -0.17% | -0.63% | 2/159 | 43.5% | 贝达药业 | 97.01% | 行业排名> |
| 2015-12-31 | 87.82% | 2.47% | -0.35% | 4/159 | 45.97% | 贝达药业 | 97.02% | 行业排名> |
| 2015-09-30 | 88.12% | 2.65% | 0.14% | 2/159 | 44.69% | 舒泰神 | 94.38% | 行业排名> |
| 2015-06-30 | 88% | 2% | 0.67% | 2/159 | 45% | 贝达药业 | 96.95% | 行业排名> |
| 2015-03-31 | 87.42% | 2% | 2% | 2/159 | 43.46% | 舒泰神 | 94.4% | 行业排名> |